5Metis key facts
as of Oct 2026- Operator of an agricultural company intended to deliver novel modes of action not currently found in the agrichemical industry.
- 5Metis is valued at approximately $30.0M as of Oct 2026 (last reported valuation).
- It has raised $15.8M across 4 recorded rounds; the latest was Seed Round ($250K) in May 2025.
- Notable investors include Gates Foundation, ARCH Venture Partners, Ospraie Ag Science(farming), 1855 Capital Partners, F3 Tech Biomanufacturing Facility & Accelerator — 6 tracked in total.
- 5Metis has filed 4 Form Ds with the SEC since 2021, most recently May 2025 ($250K sold to 8 investors).
- Status: Privately Held (backing).
5Metis's last reported valuation, Apr 2024. Nothing priced has surfaced since.
- ·Watch 5Metis: the Monday email on marks, rounds and moves
5Metis funding rounds
4 rounds5Metis valuation
5Metis's last reported valuation was $30 million in Apr 2024. No priced round, secondary trade or fund mark has surfaced since.
How much has 5Metis raised?
5Metis has raised $15.8 million across 4 recorded rounds since 2021. The largest was a $9.4 million early-stage round in Sep 2021; the most recent was a $250,000 seed round in May 2025.
5Metis has filed 4 Form Ds with the SEC since 2021, most recently in May 2025 ($250,000 sold to 8 investors).
5Metis investors
6 investors are on record for 5Metis, including Gates Foundation, ARCH Venture Partners, Ospraie Ag Science(farming) and 1855 Capital Partners. The seed round in May 2025 drew 8 investors.
About 5Metis
Operator of an agricultural company intended to deliver novel modes of action not currently found in the agrichemical industry. The company combines boron-based small molecule discovery and synthetic biology to discover new modes of action, enabling farmers to avail of the service to boost crop protection and crop health.
- Sector
- Materials and Resources
- HQ
- Durham, NC, United States
- Founded
- 2021
- Employees
- 13
- Website
- 5metis.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.